Joel C Sunshine

Dr. Joel C Sunshine


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PNPeter P. Nghiem
Peter P. Nghiem
SBShailender Bhatia
Shailender Bhatia
ELEvan J. Lipson
Evan J. Lipson
RKRagini R. Kudchadkar
Ragini R. Kudchadkar
NMNatalie J. Miller
Natalie J. Miller
MCMartin A. Cheever
Martin A. Cheever
Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma often responds to chemotherapy, but responses are transient. Blocking the programmed death 1 (PD-1) immune inhibitory pathway is of interest, because these tumors often express PD-L1, and MCPyV-specific T cells express PD-1. In this multicenter, phase 2, noncontrolled study, we assigned adults with advanced Merkel-cell carcinoma who had received no previous systemic therapy to receive pembrolizumab (anti–PD-1) at a dose of 2 mg per kilogram of body weight every 3 weeks. The primary end point was the objective response rate according to Response Evaluation Criteria in Solid Tumors, version 1.1. Efficacy was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing. A total of 26 patients received at least one dose of pembrolizumab. The objective response rate among the 25 patients with at least one evaluation during treatment was 56% (95% confidence interval [CI], 35 to 76); 4 patients had a complete response, and 10 had a partial response. With a median follow-up of 33 weeks (range, 7 to 53), relapses occurred in 2 of the 14 patients who had had a response (14%). The response duration ranged from at least 2.2 months to at least 9.7 months. The rate of progression-free survival at 6 months was 67% (95% CI, 49 to 86). A total of 17 of the 26 patients (65%) had virus-positive tumors. The response rate was 62% among patients with MCPyV-positive tumors (10 of 16 patients) and 44% among those with virus-negative tumors (4 of 9 patients). Drug-related grade 3 or 4 adverse events occurred in 15% of the patients. In this study, first-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56%. Responses were observed in patients with virus-positive tumors and those with virus-negative tumors. (Funded by the National Cancer Institute and Merck; ClinicalTrials.gov number, NCT02267603.)

1 July 2003 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
ASAmy F. Subar
Amy F. Subar
VKVictor Kipnis
Victor Kipnis
RTRichard P. Troiano
Richard P. Troiano
DMDouglas Midthune
Douglas Midthune
DSDale A. Schoeller
Dale A. Schoeller
ASArthur Schatzkin
Arthur Schatzkin
This paper describes the Observing Protein and Energy Nutrition (OPEN) Study, conducted from September 1999 to March 2000. The purpose of the study was to assess dietary measurement error using two self-reported dietary instruments—the food frequency questionnaire (FFQ) and the 24-hour dietary recall (24HR)—and unbiased biomarkers of energy and protein intakes: doubly labeled water and urinary nitrogen. Participants were 484 men and women aged 40–69 years from Montgomery County, Maryland. Nine percent of men and 7% of women were defined as underreporters of both energy and protein intake on 24HRs; for FFQs, the comparable values were 35% for men and 23% for women. On average, men underreported energy intake compared with total energy expenditure by 12–14% on 24HRs and 31–36% on FFQs and underreported protein intake compared with a protein biomarker by 11–12% on 24HRs and 30–34% on FFQs. Women underreported energy intake on 24HRs by 16–20% and on FFQs by 34–38% and underreported protein intake by 11–15% on 24HRs and 27–32% on FFQs. There was little underreporting of the percentage of energy from protein for men or women. These findings have important implications for nutritional epidemiology and dietary surveillance.

1 August 2015 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
JSJoel C Sunshine
Joel C Sunshine
JTJanis M. Taube
Janis M. Taube

7 May 2009 in Nano Letters
Verified
Journal Article
Closed access
JLJae-Seung Lee
Jae-Seung Lee
JGJordan J. Green
Jordan J. Green
KLKevin T. Love
Kevin T. Love
JSJoel C Sunshine
Joel C Sunshine
RLRobert Langer
Robert Langer
DADaniel G. Anderson
Daniel G. Anderson

30 October 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
JDJulie Stein Deutsch
Julie Stein Deutsch
ACAshley Cimino-Mathews
Ashley Cimino-Mathews
ETElizabeth Thompson
Elizabeth Thompson
MPMariano Provencio
Mariano Provencio
PFPatrick M. Forde
Patrick M. Forde
JTJanis M. Taube
Janis M. Taube
Neoadjuvant immunotherapy plus chemotherapy improves event-free survival (EFS) and pathologic complete response (0% residual viable tumor (RVT) in primary tumor (PT) and lymph nodes (LNs)), and is approved for treatment of resectable lung cancer. Pathologic response assessment after neoadjuvant therapy is the potential analog to radiographic response for advanced disease. However, %RVT thresholds beyond pathologic complete response and major pathologic response (≤10% RVT) have not been explored. Pathologic response was prospectively assessed in the randomized, phase 3 CheckMate 816 trial (NCT02998528), which evaluated neoadjuvant nivolumab (anti-programmed death protein 1) plus chemotherapy in patients with resectable lung cancer. RVT, regression and necrosis were quantified (0–100%) in PT and LNs using a pan-tumor scoring system and tested for association with EFS in a prespecified exploratory analysis. Regardless of LN involvement, EFS improved with 0% versus >0% RVT-PT (hazard ratio = 0.18). RVT-PT predicted EFS for nivolumab plus chemotherapy (area under the curve = 0.74); 2-year EFS rates were 90%, 60%, 57% and 39% for patients with 0–5%, >5–30%, >30–80% and >80% RVT, respectively. Each 1% RVT associated with a 0.017 hazard ratio increase for EFS. Combining pathologic response from PT and LNs helped differentiate outcomes. When compared with radiographic response and circulating tumor DNA clearance, %RVT best approximated EFS. These findings support pathologic response as an emerging survival surrogate. Further assessment of the full spectrum of %RVT in lung cancer and other tumor types is warranted. ClinicalTrials.gov registration: NCT02998528.

1 January 2014 in Biomaterials
Verified
Journal Article
Closed access
JSJoel C Sunshine
Joel C Sunshine
KPKarlo Perica
Karlo Perica
JSJonathan P. Schneck
Jonathan P. Schneck
JGJordan J. Green
Jordan J. Green